Envista Holdings Corporation
NVST
$28.07
-0.04%
Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets a comprehensive portfolio of dental consumables, equipment, and services, operating through two primary segments: Specialty Products & Technologies and Equipment & Consumables. As a market leader in dental implants and orthodontics, Envista holds a distinct competitive position with its well-known brands like Nobel Biocare and Ormco, serving dental professionals worldwide. The current investor narrative centers on the company's ongoing transformation and growth acceleration, highlighted by a 14.96% year-over-year revenue increase in the latest quarter, which has fueled a 38.9% stock price surge over the past year. However, the stock's recent 4.4% single-day drop and mixed analyst actions suggest ongoing debate about the sustainability of this momentum and the company's ability to maintain margin expansion amidst competitive pressures.…
NVST
Envista Holdings Corporation
$28.07
NVST 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Envista Holdings Corporation's 12-month outlook, with a consensus price target around $30.57 and implied upside of +8.9% versus the current price.
Average Target
$30.57
0 analysts
Implied Upside
+8.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $35
Analyst target range
Analyst coverage is robust, with 14 analysts covering Envista, and the consensus recommendation is 'Buy' with a mean rating of 2.19 (where 1 is Strong Buy and 5 is Sell). The average target price is $29.43, implying a 7.5% upside from the current price of $27.38. The distribution shows a bullish tilt, with 7 Buy ratings, 6 Neutral, and 1 Sell, indicating a generally positive but cautious sentiment. The target price range spans from $21.00 (low) to $35.00 (high), reflecting a wide spread of $14.00, which signals significant uncertainty about the company's future performance. The high target of $35 assumes continued strong growth and margin expansion, while the low target of $21 prices in potential competitive pressures or a slowdown in dental spending. Recent institutional actions have been mixed, with Barclays reiterating Overweight and Stifel maintaining Buy, while Mizuho upgraded from Underperform to Neutral, suggesting a cautiously optimistic outlook. The wide target range and mixed ratings indicate that while analysts see upside potential, they are not fully convinced of the sustainability of Envista's turnaround, warranting a balanced approach for investors.
NVST Technical Analysis
Envista's stock is in a clear recovery uptrend, with a 1-year price change of +38.9% and a year-to-date gain of +26.2%, significantly outperforming the S&P 500's 21.5% and 12.7% respective gains. The current price of $27.38 sits at 90% of its 52-week range (low $18.77, high $30.42), indicating strong momentum and investor confidence, though it also suggests the stock may be approaching overbought territory. The 6-month price change of -5.9% reflects a period of consolidation after a strong rally, but the stock has since recovered from its May lows, demonstrating resilience.
Beta
0.86
0.86x market volatility
Max Drawdown
-26.0%
Largest decline past year
52-Week Range
$19-$30
Price range past year
Annual Return
+34.8%
Cumulative gain past year
| Period | NVST Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | +2.9% |
| 3m | +20.9% | +5.0% |
| 6m | -3.1% | +13.9% |
| 1y | +34.8% | +20.4% |
| ytd | +29.4% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVST Fundamental Analysis
Envista's revenue trajectory has been robust, with the latest quarter (Q4 2025) reporting revenue of $750.6 million, a 14.96% year-over-year increase, accelerating from the 8.4% growth seen in Q3 2025. The company's revenue segments show Specialty Products & Technologies contributing $1.21 billion and Equipment & Consumables $679.3 million, with the specialty segment driving growth. This acceleration is a positive signal for the investment case, indicating strong demand for Envista's dental implant and orthodontic products. However, the company's profitability has been inconsistent, with Q4 2025 net income of $32.9 million (net margin 4.4%) and a gross margin of 55.0%, but Q3 2025 saw a net loss of -$30.3 million due to a one-time tax charge. The operating margin of 10.1% in Q4 is an improvement from 7.4% in Q2, suggesting operational leverage is being realized. Envista's balance sheet is solid, with a current ratio of 2.38, debt-to-equity of 0.51, and free cash flow of $230.4 million over the trailing twelve months, providing ample liquidity for growth initiatives and debt servicing.
Quarterly Revenue
$750600000.0B
2025-12
Revenue YoY Growth
+15.0%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$230400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVST Overvalued?
Given that Envista is profitable, the PE ratio is the primary valuation metric. The trailing PE is 77.5x, while the forward PE is 17.4x, indicating that the market expects significant earnings growth, as reflected in the consensus EPS estimate of $1.88 for the next fiscal year. This wide gap suggests the market is pricing in a substantial earnings recovery, which is supported by the company's recent revenue acceleration and margin expansion. Compared to the industry average PE of 22.5x (based on sector data), Envista's forward PE of 17.4x represents a 23% discount, suggesting the stock is undervalued relative to peers on a forward basis. However, the trailing PE is at a premium due to depressed past earnings, highlighting the importance of forward-looking metrics. Historically, Envista's PE has ranged from 18.7x to 693x over the past five years, with the current forward PE near the lower end of that range, indicating that the market's expectations are not overly optimistic and there is room for multiple expansion if the company delivers on its growth trajectory.
PE
77.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple